10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference [Accessibility Statement] Skip NavigationPLEASANTON, Calif., Feb. 19, 2026 /PRNewswire/ -- [10x Genomics, Inc.](Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, at 11:50 a.m. Eastern Time.Interested parties may access a live webcast of the fireside chat on the "I ...

Core Insights - Torex Gold Resources Inc. reported a transformational year in 2025, achieving significant milestones including the completion of the Media Luna Project and returning to strong free cash flow [2][4]. Financial Performance - The company achieved record annual revenue of $1.3 billion and record annual adjusted EBITDA of $730 million [4][6]. - Annual payable production reached 376,364 gold equivalent ounces, slightly below the guidance of 400,000 to 450,000 ounces [6]. - The average realized gold price for the year was $3,612 per ounce, contributing to a record all-in sustaining costs margin of 51% [4][6]. Operational Highlights - In Q4 2025, payable production was 114,844 gold equivalent ounces, with expectations to maintain production levels through 2026 [3][17]. - The Media Luna Project is on track to achieve steady-state production of 7,500 tonnes per day by mid-2026 [3][5]. - The company maintained a lost-time injury frequency of 0.07 per million hours worked, marking one of its safest years [6][19]. Capital Management - Torex executed an inaugural return of capital program, including a quarterly dividend of C$0.15 per share and repurchased over 825,000 shares during the year [9][11]. - The company ended the year with $426.3 million in available liquidity, including $119.5 million in cash [6][19]. Growth Strategy - Torex expanded its portfolio through acquisitions of Prime Mining and Reyna Silver, enhancing its growth potential in Northern Mexico and Nevada [2][6]. - The company plans to invest a record $77 million in exploration and drilling in 2026, focusing on near-mine opportunities [6][10]. CEO Transition - Jody Kuzenko will retire as President and CEO on June 17, 2026, with Andrew Snowden set to assume the role [7].

Core Insights - Tempus AI, Inc. (TEM) is set to report its fourth-quarter 2025 results on February 24, with expectations of an 82.8% year-over-year revenue increase to $366.8 million [2][7] - The company reported an adjusted loss of 11 cents per share in the last quarter, which was better than the Zacks Consensus Estimate of a loss of 16 cents [1] - Tempus has seen a share price decline of 32.9% in the fourth quarter due to macroeconomic challenges, despite strong momentum from strategic acquisitions and product launches [3][7] Financial Performance - The Zacks Consensus Estimate for loss per share has remained unchanged at 2 cents over the past 30 days [2] - The company's earnings estimate revision trend shows consistent expectations for the current quarter and the next, with losses projected at -0.02 for Q4 and -0.13 for Q1 2026 [3] - In the previous quarter, Tempus achieved a gross profit improvement of 98.4% year-over-year, and adjusted EBITDA turned positive, indicating progress towards profitability [14] Market Position and Competitive Landscape - Tempus trades at a forward price-to-sales (P/S) ratio of 5.82X, which is above the industry average of 5.66X and higher than competitors like 10x Genomics (3.83X) and SOPHiA GENETICS (3.69X) [16] - The Zacks Medical Info Systems industry experienced a loss of 21.6% during the same period, while the S&P 500 gained 3.3% [4] Strategic Developments - Recent collaborations include a multi-year partnership with Whitehawk Therapeutics for oncology treatments and a selection by the Advanced Research Projects Agency for Health to provide testing services [8] - The Genomics segment is expected to show improvement due to growth in oncology testing and hereditary sequencing, while the Data and Services business is likely to benefit from strong demand for proprietary data licensing and AI solutions [9][10] - Tempus has enhanced its capabilities through the acquisition of Paige, an AI leader in digital pathology, and expanded its collaboration with Northwestern Medicine to integrate AI into clinical workflows [12] Future Outlook - The AI market is anticipated to grow rapidly, positioning Tempus to capitalize on emerging opportunities in healthcare [17] - Despite recent upsides, the company's premium valuation and lack of near-term profitability may limit immediate gains [18]

Group 1: Ark Invest's Strategic Moves - Ark Invest acquired shares in Tempus AI Inc., Kodiak AI Inc., and WeRide Inc. on Monday [1] - The firm significantly increased its position in Tempus AI by purchasing 1,192 shares through the ARK Genomic Revolution ETF and an additional 6,545 shares via the ARK Innovation ETF, totaling approximately $523,253 [2] - Ark Invest also made a notable purchase of 47,752 shares of Kodiak AI Inc. through the ARK Autonomous Technology & Robotics ETF, valued at approximately $427,380 [4] - The firm acquired 48,260 shares of WeRide Inc. through ARKQ, resulting in a total transaction value of approximately $417,449 [5] Group 2: Notable Transactions and Market Context - Former House Speaker Nancy Pelosi's spouse exercised 50 call options on Tempus AI, adding 5,000 shares to the portfolio, valued between $50,000 and $100,000 [3] - Tempus AI's stock closed at $67.63, while Kodiak AI's stock closed at $8.95, marking a decrease of 4.58% from the previous session [2][4] - WeRide Inc. reported that its fleet has surpassed 1,000 vehicles and announced integration with Tencent's WeChat platform [5]

Core Insights - Ark Invest has released its 10th annual "Big Ideas" list for 2026, highlighting key themes and investment opportunities following a strong performance in 2025, where its ETFs outperformed the S&P 500 [1][2] Group 1: Thematic Trends - "The Great Acceleration" is identified as a central theme for 2026, impacting various technologies such as AI, public blockchains, robotics, energy storage, and multiomics, which is expected to drive significant GDP growth [2][3] - Capital investment in disruptive innovation platforms could contribute an additional 1.9 percentage points to annualized real GDP growth during this decade, focusing on innovations like robotaxis and AI agents [3] Group 2: Investment Opportunities in ETFs - Ark's thematic ETFs are aligned with the Big Ideas for 2026, with U.S. ETFs and public companies holding 12% of total Bitcoin supply, and Bitcoin ETF balances increasing by 19.7% in 2025 [4] - The Ark Autonomous Technology & Robotics ETF and Ark Space & Defense Innovation ETF were the top performers among Ark's ETFs, achieving gains of 49.8% and 49.2% respectively in 2025 [4] Group 3: Key Companies and Stocks - Several publicly traded companies are highlighted as key players in the 2026 themes, including Coinbase Global, Circle Internet Group, and Robinhood Markets for the tokenized assets theme [8] - For the Multiomics theme, notable stocks include Illumina Inc, CRISPR Therapeutics, and 10x Genomics, which are expected to drive advancements in healthcare [9] - Waymo, owned by Alphabet Inc, is recognized as a disruptor in the autonomous vehicles sector, impacting competitors like Uber and Lyft [10] - Tesla Inc, while not frequently mentioned, is central to multiple Big Ideas, including autonomous vehicles and distributed energy, and remains a significant holding in Ark's portfolios [11]

Industry Overview - The Medical Info Systems industry is rapidly expanding due to innovations in healthcare resource management, patient data handling, and integrated digital care delivery [1] - Companies in this industry develop and market healthcare information systems, providing software and hardware solutions for secure access to real-time clinical, administrative, and financial data [4] Market Growth and Trends - The use of artificial intelligence (AI) in healthcare is projected to grow at a CAGR of 38.6% from 2025 to 2030, driven by demand for enhanced diagnostic accuracy and personalized medicine [2] - The global Smart Healthcare Products market was valued at $280.48 billion in 2024 and is expected to reach $796.36 billion by 2032, growing at a CAGR of 15.37% [5] - Remote patient monitoring and telehealth services are experiencing significant growth due to increased awareness of continuous patient monitoring devices [5] Key Players - Doximity (DOCS) is a market leader in physician engagement, covering over 80% of U.S. doctors, with a subscription-based revenue model and a total addressable market of $18.55 billion [17] - 10x Genomics (TXG) develops products for analyzing biological systems, with a Zacks Consensus Estimate indicating a 72.4% improvement in earnings from 2024 to 2025 [21][22] - Omnicell (OMCL) focuses on medication management solutions and is expected to achieve a revenue CAGR of 2.8% from 2025 to 2027 [25] Financial Performance - The Medical Info Systems industry has underperformed the S&P 500 and the Zacks Medical sector, losing 7.7% over the past year compared to the sector's growth of 24.7% [11] - The industry is currently trading at a forward price-to-sales (P/S) ratio of 4.65X, lower than the S&P 500's 5.65X and the sector's 2.35X [14] Cybersecurity Concerns - As healthcare systems become more digital, cybersecurity has emerged as a critical concern, with rising instances of ransomware and cyberattacks targeting healthcare organizations [7][8]

Core Insights - Ark Invest has introduced its "big ideas" for 2026 through a series of custom images called "ARKmoji," inviting followers to interpret the themes behind each image [1][2] Group 1: AI Agents - The first ARKmoji represents agentic AI, with user interpretations divided among AI Agent Takeover (37.5%), AI Consumer Op System (32.2%), and Build-Your-Own-Agent (25.7%) [3] - Relevant holdings in Ark's portfolio include Palantir Technologies Inc. (NASDAQ:PLTR), Tempus AI Inc. (NASDAQ:TEM), and Shopify Inc. (NASDAQ:SHOP) [3] Group 2: Genomics - The second ARKmoji, depicting a DNA helix, suggests a focus on genomics, with votes split among molecular diagnostics (34.7%), aging backwards (21.3%), multiomics (25.2%), and the software layer of biology (18.8%) [4] - Key stocks in this area include Crispr Therapeutics AG (NASDAQ:CRSP), 10x Genomics Inc. (NASDAQ:TXG), and Illumina Inc. (NASDAQ:ILMN) [4] Group 3: The Space Race - The third ARKmoji features a rocket, with 55% of users voting for reusable rockets, while 27.5% favored the broader theme of "The Space Race" [5] - Holdings in this sector are primarily found in Ark's Space & Defense Innovation ETF (BATS:ARKX), including Rocket Lab Corp. (NASDAQ:RKLB), Iridium Communications Inc. (NASDAQ:IRDM), and Intuitive Machines Inc. (NASDAQ:LUNR) [5] Group 4: Cryptocurrencies / Tokenization - The fourth ARKmoji shows a dollar note on a blockchain, indicating a focus on cryptocurrencies and tokenization, with 36.1% voting for cryptocurrencies and 41.1% for tokenization [6][7] - Relevant stocks include Coinbase Global Inc. (NASDAQ:COIN), BitMine Immersion Technologies Inc. (NYSEAMERICAN:BMNR), Bullish (NYSE:BLSH), and Robinhood Markets Inc. (NASDAQ:HOOD) [7] Group 5: Robotics - The fifth ARKmoji, depicting a robot, received 59% of votes for "Robotics," while 25.6% chose "I, Robot" [8] - Prominent holdings in this theme include Tesla Inc. (NASDAQ:TSLA), Kratos Defense & Security Solutions Inc. (NASDAQ:KTOS), and AeroVironment Inc. (NASDAQ:AVAV) [8] Group 6: The Great Acceleration - The final ARKmoji shows a cluster of arrows, suggesting exponential growth, with "The Great Acceleration" receiving 55.8% of votes, followed by "S-Curves Feeding S-Curves" at 26% [9] - The specific stock or idea related to this theme remains unclear, but it may involve the convergence of various technologies and ideas [10]

Company Performance - 10x Genomics announced preliminary Q4 and full year 2025 results, reporting approximately $599 million in revenue for the full year and $166 million in Q4, exceeding the high end of their Q4 guidance [2] - The company generated about $40 million in cash, bringing its balance sheet to over $0.5 billion [2] Management Commentary - The CEO expressed pride in the team's performance amidst significant upheavals in various end markets, highlighting strong execution throughout the year [3] - The company experienced positive momentum in key metrics driving business fundamentals, multiple new product launches, and a strengthened balance sheet, positioning the company in its strongest state ever [3]

Core Viewpoint - CareDx, Inc. has announced a strategic collaboration with 10x Genomics to establish ImmuneScape, a multiomics research initiative aimed at enhancing healthcare solutions for transplant patients and caregivers [1] Group 1: Company Overview - CareDx, Inc. is a leading precision medicine company focused on the discovery, development, and commercialization of high-value healthcare solutions for transplant patients and caregivers [1] - 10x Genomics is recognized as a leader in single cell and spatial biology [1] Group 2: Strategic Collaboration - The collaboration between CareDx and 10x Genomics is aimed at establishing ImmuneScape, which is designed to elucidate complex biological systems [1]

Core Insights - Tempus AI (TEM) reported a non-GAAP profit in Q3 2025, driven by growth in genomics testing and data services, with revenue increasing by 84.7% year over year to $334.2 million and adjusted EBITDA reaching $1.5 million [1][8] - The stock holds a Zacks Rank 3 (Hold) with a VGM Score of D, indicating weaknesses in value but stronger momentum [1][13] Business Mix and Growth Drivers - Genomics revenue more than doubled to $252.9 million, with oncology testing contributing $139.5 million and hereditary testing $102.6 million [2] - Data and services revenue grew by 26.1%, with Insights increasing by 37.6%, and clinical tests delivered reached 217,000, up 33% year over year [2][3] Pricing Catalysts - Management is transitioning a significant portion of xT CDx volume to FDA-approved tracks and plans further FDA submissions, expecting to submit xT for approval by the end of 2025 [4] - These initiatives aim to enhance average selling prices and unit economics over time, although average realized pricing remains below peer levels until approvals are secured [5] Revenue Recognition and Demand - Strong customer demand for Data & Services is evident, with mid-20% booking growth year over year and approximately $150 million in new contracts [6] - However, the multi-year recognition of bookings may delay near-term revenue recognition and margin improvement [7] Profitability and Future Guidance - The company anticipates 2025 revenue of approximately $1.265 billion, implying around 80% annual growth and positive adjusted EBITDA for the full year [8] - Management expects about $20 million of adjusted EBITDA in Q4 2025, with continued EPS improvement projected through 2026 and potential positive EPS in 2027 [11] Financial Position - Tempus AI ended Q3 with $764.3 million in cash and marketable securities, providing the capacity for ongoing investments in AI compute and regulatory initiatives [12] Market Position and Performance Expectations - The stock's Zacks Rank 3 (Hold) and VGM Score of D suggest expectations for market-like performance in the near term, with a focus on estimate revisions related to pricing, FDA decisions, and reimbursement progress [13]